Welcome to CDC stacks | Case-Fatality Rates and Sequelae Resulting from Neisseria meningitidis Serogroup C Epidemic, Niger, 2015 - 42767 | Emerging Infectious Diseases
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Case-Fatality Rates and Sequelae Resulting from Neisseria meningitidis Serogroup C Epidemic, Niger, 2015
Filetype[PDF-1.39 MB]


No Related Documents.
You May Also Like:
  1. Global epidemiology of invasive meningococcal disease
    Personal Author:
    Jafri, Rabab Z; Ali, Asad; Messonnier, Nancy E; Tevi-Benissan, Carol; Durrheim, David; Eskola, Juhani; Fermon, Florence; Klugman, Keith P; Ramsay, Mary; Sow, Samba; Zhujun, Shao; Bhutta, Zulfiqar A; Abramson, Jon;
    Published:
    Sep 10 2013
    Source:
    Popul Health Metr. 2013; 11:17.
    Description:
    Neisseria meningitidis is one of the leading causes of bacterial meningitis globally and can also cause sepsis, pneumonia, and other manifestations. In countries with high endemic rates, the disease burden places an immense strain on the public healt...
    File Type:
    Filetype[PDF - 483.74 KB]
  2. Emergence of epidemic Neisseria meningitidis serogroup C in Niger, 2015: an analysis of national surveillance data
    Personal Author:
    Sidikou, Fati; Zaneidou, Maman; Alkassoum, Ibrahim; Schwartz, Stephanie; Issaka, Bassira; Obama, Ricardo; Lingani, Clement; Tate, Ashley; Ake, Flavien; Sakande, Souleymane; Ousmane, Sani; Zanguina, Jibir; Seidou, Issaka; Nzeyimana, Innocent; Mounkoro, Didier; Abodji, Oubote; Wang, Xin; Taha, Muhamed-Kheir; Moulia-Pelat, Jean Paul; Pana, Assimawe; Kadade, Goumbi; Ronveaux, Olivier; Novak, Ryan; Oukem-Boyer, Odile Ouwe Missi; Meyer, Sarah;
    Published:
    Aug 23 2016
    Source:
    Lancet Infect Dis. 16(11):1288-1294.
    Description:
    Background : To combat Neisseria meningitidis serogroup A epidemics in the meningitis belt of sub-Saharan Africa, a meningococcal serogroup A conjugate vaccine (MACV) has been progressively rolled out since 2010. We report the first meningitis epidem...
    File Type:
    Filetype[PDF - 320.91 KB]
  3. Meningococcal conjugate vaccines: optimizing global impact
    Personal Author:
    Terranella, Andrew; Cohn, Amanda; Clark, Thomas;
    Published:
    Sep 21 2011
    Source:
    Infect Drug Resist. 2011; 4:161-169.
    Description:
    Meningococcal conjugate vaccines have several advantages over polysaccharide vaccines, including the ability to induce greater antibody persistence, avidity, immunologic memory, and herd immunity. Since 1999, meningococcal conjugate vaccine programs ...
    File Type:
    Filetype[PDF - 171.94 KB]
  4. Surveillance of Bacterial Meningitis, Ethiopia, 2012–2013
    Personal Author:
    Mihret, Wude; Lema, Tsehaynesh; Merid, Yared; Kassu, Afework; Abebe, Workeabeba; Moges, Beyene; Tenna, Admasu; Woldegebriel, Fitsum; Yidnekachew, Melaku; Mekonnen, Wondale; Ahmed, Arslan; Yamuah, Lawrence; Silamsaw, Mezgebu; Petros, Beyene; Oksnes, Jan; Rosenqvist, Einar; Ayele, Samuel; Aseffa, Abraham; Caugant, Dominique A.; Norheim, Gunnstein;
    Published:
    Jan 2016
    Source:
    Emerg Infect Dis. 22(1):75-78.
    Description:
    Among 139 patients with suspected bacterial meningitis in Ethiopia, 2012-2013, meningococci (19.4%) and pneumococci (12.9%) were the major disease-causing organisms. Meningococcal serogroups detected were A (n = 11), W (n = 7), C (n = 1), and X (n = ...
    File Type:
    Filetype[PDF - 513.87 KB]
  5. Effect of a vaccine to prevent serogroup A N meningitidis epidemics in Africa
    Personal Author:
    Meyer, Sarah A; Novak, Ryan T;
    Published:
    May 22 2017
    Source:
    Lancet Infect Dis. 17(8):789-790.
    File Type:
    Filetype[PDF - 540.01 KB]